Free US stock valuation multiples and PEG ratio analysis to identify reasonably priced growth companies. Our valuation framework helps you find stocks with the right balance of growth and value characteristics.
As of 2026-04-02, BioCryst Pharmaceuticals Inc. (BCRX) trades at a current price of $9.02, marking a 3.84% decline in recent trading sessions. This analysis examines key technical levels, prevailing market context for the biotech sector, and potential near-term scenarios for the stock, without making any investment recommendations. No recent earnings data is available for BCRX as of the current date, so market participants are largely relying on technical signals, sector trends, and potential up
What’s the outlook for BioCryst (BCRX) Stock this year | Price at $9.02, Down 3.84% - Insider Buying
BCRX - Stock Analysis
3377 Comments
537 Likes
1
Malta
Influential Reader
2 hours ago
This feels like it knows me personally.
👍 95
Reply
2
Khawaja
New Visitor
5 hours ago
Indices are experiencing mixed performance, highlighting the need for cautious positioning.
👍 149
Reply
3
Dellamae
Senior Contributor
1 day ago
This feels like a strange alignment.
👍 157
Reply
4
Audencio
Daily Reader
1 day ago
I read this and now I need water.
👍 82
Reply
5
Seph
Active Contributor
2 days ago
US stock return on invested capital analysis and economic value added calculations to identify truly exceptional businesses with durable competitive advantages. Our quality metrics help you find companies that generate superior returns on capital employed in their business operations. We provide ROIC analysis, economic value added calculations, and capital efficiency metrics for comprehensive quality assessment. Find quality businesses with our comprehensive quality analysis and return metrics for long-term investment success.
👍 104
Reply
Disclaimer: Not investment advice. For informational purposes only. Past performance does not guarantee future results. Trading involves substantial risk of loss.